GPLB · Green Planet Bioengineering Co Ltd

Management's Discussion and Analysis confirms the Company had no active business operations for the three months ended March 31, 2026, directly explaining the absence of revenue and the nature of reported losses. This dormant state resulted in a GAAP net loss of -$10.9K, a 60% year-over-year widening from -$6.8K in Q1 FY2025. The increased loss stems from administrative expenses incurred to maintain the corporate shell amid zero operational activity, underscoring the fixed-cost burden in a no-revenue environment. Investors should note this trajectory reflects not business contraction but continuation of inactivity, with implications for escalating cash needs absent any revenue catalysts.

Cash flow from operations deteriorated sharply to -$16.6K, versus -$6.9K YoY, mirroring the deeper net loss while incorporating non-cash adjustments and working capital shifts typical of minimal activity. This burn rate highlights liquidity strain in a period defined by dormancy, where even basic compliance and administrative functions consume resources. The lack of operational inflows leaves the Company fully exposed to external funding dependencies, as no financing activities are detailed in the supported metrics.

Management commentary in the filing emphasizes that these results involve significant risks and uncertainties, particularly around business strategy, future revenues, anticipated costs, and expenses. Liquidity and capital resources are explicitly tied to this inactive profile, with no active operations generating any cash or progress toward commercialization. The outlook remains constrained, as the Company's ability to implement future business plans or generate sufficient revenue is directly influenced by securing adequate financing or identifying profitable opportunities. Without such support, the pattern of deepening losses and cash outflows persists, as evidenced by the 60% YoY net income decline and intensified operating burn.

No unregistered sales of equity securities were reported, signaling no immediate capital raises during the period. Certifications by Jordan Weingarten, President and CFO, affirm review of the report under 18 U.S.C., reinforcing accountability amid these challenges. Overall, this Q1 reflects a holding pattern with heightened vulnerability, where execution of any bioengineering ambitions depends entirely on external capital access. Investors face elevated uncertainty until financing materializes to enable operations beyond maintenance.